309 related articles for article (PubMed ID: 12235251)
1. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
2. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
[TBL] [Abstract][Full Text] [Related]
3. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
4. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Sato M; Bryant HU; Iversen P; Helterbrand J; Smietana F; Bemis K; Higgs R; Turner CH; Owan I; Takano Y; Burr DB
J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile.
Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G
Menopause; 2005; 12(5):589-600. PubMed ID: 16145313
[TBL] [Abstract][Full Text] [Related]
8. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
Helvering LM; Liu R; Kulkarni NH; Wei T; Chen P; Huang S; Lawrence F; Halladay DL; Miles RR; Ambrose EM; Sato M; Ma YL; Frolik CA; Dow ER; Bryant HU; Onyia JE
Mol Pharmacol; 2005 Nov; 68(5):1225-38. PubMed ID: 16079270
[TBL] [Abstract][Full Text] [Related]
11. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
13. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays.
Ashby J; Odum J; Foster JR
Regul Toxicol Pharmacol; 1997 Jun; 25(3):226-31. PubMed ID: 9237325
[TBL] [Abstract][Full Text] [Related]
14. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
[TBL] [Abstract][Full Text] [Related]
15. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.
Kauffman RF; Bensch WR; Roudebush RE; Cole HW; Bean JS; Phillips DL; Monroe A; Cullinan GJ; Glasebrook AL; Bryant HU
J Pharmacol Exp Ther; 1997 Jan; 280(1):146-53. PubMed ID: 8996192
[TBL] [Abstract][Full Text] [Related]
16. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
17. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats.
Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG
Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of development and growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by the antiestrogen U 23,469 and effects on estrogen and progesterone receptors.
Tsai TL; Katzenellenbogen BS
Cancer Res; 1977 May; 37(5):1537-43. PubMed ID: 404032
[TBL] [Abstract][Full Text] [Related]
19. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Carthew P; Edwards RE; Nolan BM
Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
Sato M; Kim J; Short LL; Slemenda CW; Bryant HU
J Pharmacol Exp Ther; 1995 Mar; 272(3):1252-9. PubMed ID: 7891341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]